{
    "clinical_study": {
        "@rank": "109396", 
        "arm_group": [
            {
                "arm_group_label": "TTP488 5mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to evaluate the efficacy and safety of TTP488 in patients with mild\n      Alzheimer's disease.   Patients will receive either TTP488 or placebo with a patient's\n      participation lasting approximately 18 months."
        }, 
        "brief_title": "Evaluation of the Efficacy and Safety of TTP488 in Patients With Mild Alzheimer's Disease", 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": "Alzheimer Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of probable Alzheimer Disease (AD) with documented evidence of progression\n             of disease\n\n          -  Mini Mental State Examination (MMSE) score of 21-26, inclusive\n\n          -  Rosen-Modified Hachinski Ischemia Score less than or equal to 4\n\n          -  Brain magnetic resonance imaging (MRI) consistent with the diagnosis of probable AD\n\n          -  Concurrent use of cholinesterase inhibitor or memantine with stable dose for at least\n             3 months prior to randomization\n\n          -  Caregiver willing to participate and be able to attend clinic visits with patient\n\n          -  Ability to ingest oral medications\n\n        Exclusion Criteria:\n\n          -  Significant neurological or psychiatric disease other than Alzheimer's disease\n\n          -  Participants with evidence or history of severe drug allergies (resulting in dyspnea\n             or severe rash).\n\n          -  Any contraindications to MRI  (e.g., clinically significant claustrophobia,\n             non-removable ferromagnetic implants).\n\n          -  Any contraindications to the FDG-PET study (e.g. allergy to any component of the FDG\n             dose) in the mild AD dementia subject cohort undergoing a PET scan.\n\n          -  Previous exposure to investigational or non-investigational therapies for Alzheimer's\n             disease that are being investigated for possible disease modification activity\n\n          -  History of cancer within the last 5 years. Cutaneous basal cell, squamous cell\n             cancer, resolved by excision, or non-progressive prostate cancer not requiring\n             treatment are allowed.\n\n          -  Women of childbearing potential"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "800", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080364", 
            "org_study_id": "TTP488-301"
        }, 
        "intervention": [
            {
                "arm_group_label": "TTP488 5mg", 
                "description": "TTP488 5mg administered orally, once daily for 18 months", 
                "intervention_name": "TTP488", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo administered orally, once daily for 18 months", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Cholinesterase Inhibitors"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Alzheimer's disease", 
            "RAGE", 
            "ADAS-cog", 
            "CDR-sb"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine", 
        "overall_contact": {
            "email": "clinicaltrials@ttpharma.com", 
            "last_name": "Aaron H Burstein, PharmD"
        }, 
        "overall_official": {
            "affiliation": "TransTech Pharma", 
            "last_name": "Aaron H Burstein, PharmD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) total score", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Change from Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-sb)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080364"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Magnetic Resonance Imaging (MRI) brain volumetric measures", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Change from Baseline in Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Scan", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Change from Baseline in Neuropsychiatric Inventory (NPI)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Change from Baseline in Mini-Mental State Examination (MMSE)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Change from Baseline in Alzheimer's Disease Cooperative Study- Activities of Daily Living Inventory (ADCS-ADL)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Change from Baseline in Continuous Oral Word Association Task (COWAT)", 
                "safety_issue": "No", 
                "time_frame": "18 month"
            }, 
            {
                "measure": "Change from Baseline in Category Fluency Test (CFT)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Change from Baseline in Resource Utilization in Dementia (RUD)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Change from Baseline in Dementia Quality of Life (DEMQOL)", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Change from Baseline in Plasma Amyloid Beta", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Proportion of Responders based on ADAS-cog", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Proportion of Responders based on CDR-SB", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }
        ], 
        "source": "TransTech Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TransTech Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}